A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 755 participants.
Also called NCT06066528
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 755 participants
- Sponsor
- Registry
-
NCT06066528 -
2022-502531-18-00 -
U1111-1289-0247
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Belgium, Canada, China, Czechia, Denmark, Finland, Germany, Greece, Hungary, Japan, Netherlands, New Zealand, Poland, South Korea, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06066528. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-27 (actual); primary completion 2025-12-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
- Acronym
- SYNCHRONIZE™-2
- Condition
- Obesity
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Combination product)
- Survodutide
- Intervention (Combination product)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct06066528- Content hash
224f211d88cf6b6a9cd9c10d43a89206d8ac05480b81568944c1348f7f4f5e68